Intellia Therapeutics, Inc. (NTLA)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous Close | 47.71 |
| Open | 48.76 |
| Bid | 47.20 x 800 |
| Ask | 47.26 x 1300 |
| Day's Range | 43.49 - 50.20 |
| 52 Week Range | 38.85 - 202.73 |
| Volume | |
| Avg. Volume | 1,211,284 |
| Market Cap | 3.621B |
| Beta (5Y Monthly) | 2.14 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.06 |
| Earnings Date | Aug 03, 2022 - Aug 08, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 136.65 |
- Simply Wall St.
Investors might be losing patience for Intellia Therapeutics' (NASDAQ:NTLA) increasing losses, as stock sheds 14% over the past week
The last three months have been tough on Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) shareholders, who have seen the...
- Zacks
Intellia (NTLA) Q1 Loss Wider Than Expected, Revenues Beat
Intellia Therapeutics (NTLA) posts wider-than-expected Q1 loss while sales beat the mark. NTLA continues to advance its pipeline with developmental programs.
- Zacks
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -76.58% and 8.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
© 2022 Yahoo. All rights reserved.
